The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis
Open accessAbstract
ApoAV has been discovered recently as a novel modifier of triglyceride (TG) metabolism, but the pathways involved are currently unknown. To gain insight into the function of apoAV, adenovirus-mediated gene transfer of murine apoa5 to C57Bl/6 mice was employed. The injection of low doses of Ad-apoa5 (1-5 x 10(8) plaqueforming units/mouse) dose-dependently reduced plasma very low density lipoprotein (VLDL)-TG levels. First, we evaluated whether a reduced hepatic VLDL production contributed to the TG-lowering effect. Ad-apoa5 treatment dose-dependently diminished (29-37%) the VLDL-TG production rate without affecting VLDL particle production, suggesting that apoAV impairs the lipidation of apoB. Second, Ad-apoa5 treatment dose-dependently reduced (68-88%) the postprandial hypertriglyceridemia following an intragastric fat load, suggesting that apoAV also stimulates the lipoprotein lipase (LPL)-dependent clearance of TG-rich lipoproteins. Indeed, recombinant apoAV was found to dose-dependently stimulate LPL activity up to 2.3-fold in vitro. Accordingly, intravenously injected VLDL-like TG-rich emulsions were cleared at an accelerated rate concomitant with the increased uptake of emulsion TG-derived fatty acids by skeletal muscle and white adipose tissue in Ad-apoa5-treated mice. From these data, we conclude that apoAV is a potent stimulator of LPL activity. Thus, apoAV lowers plasma TG by both reducing the hepatic VLDL-TG production rate and by enhancing the lipolytic conversion of TG-rich lipoproteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Separation of plasma lipoproteins by density-gradient ultracentrifugation
Redgrave, T. G., Roberts, D. C. K., & West, C. E. (1975) · Analytical Biochemistry · doi:10.1016/0003-2697(75)90488-1 · Cited by 1,107
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921
Evidence that triglycerides are an independent coronary heart disease risk factor
Cullen, P. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01127-9 · Cited by 462
Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels
Pennacchio, L. A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.24.3031 · Cited by 380
van der Vliet, H. N., Sammels, M. G., Leegwater, A. C. J., Levels, J. H. M., Reitsma, P. H., Boers, W., & Chamuleau, R. A. F. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106888200 · Cited by 344
Self-citationTao, N., Gao, G.-P., Parr, M., Johnston, J., Baradet, T., Wilson, J. M., Barsoum, J., & Fawell, S. E. (2001) · Molecular Therapy · doi:10.1006/mthe.2000.0227 · Cited by 321
Very-low-density lipoprotein assembly and secretion
Shelness, G. S., & Sellers, J. A. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00008 · Cited by 309
Endothelial lipase is a major determinant of HDL level
Ishida, T., Choi, S., Kundu, R. K., Hirata, K.-I., Rubin, E. M., Cooper, A. D., & Quertermous, T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16306 · Cited by 306
Otway, S., & Robinson, D. S. (1967) · The Journal of Physiology · doi:10.1113/jphysiol.1967.sp008211 · Cited by 287
Vu-Dac, N., Gervois, P., Jakel, H., Nowak, M., Baugé, E., Dehondt, H., Staels, B., Pennacchio, L. A., Rubin, E. M., Fruchart-Najib, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212191200 · Cited by 206
Cited by
Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Claudel, T., Staels, B., & Kuipers, F. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000178994.21828.a7 · Cited by 504
Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs431 · Cited by 501
The effect of heritability and host genetics on the gut microbiota and metabolic syndrome
Lim, M. Y., You, H. J., Yoon, H. S., Kwon, B., Lee, J. Y., Lee, S., Song, Y.-M., Lee, K., Sung, J., & Ko, G. (2017) · Gut · doi:10.1136/gutjnl-2015-311326 · Cited by 345
Merkel, M., Loeffler, B., Kluger, M., Fabig, N., Geppert, G., Pennacchio, L. A., Laatsch, A., & Heeren, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411412200 · Cited by 291
Genetic determinants of plasma triglycerides
Johansen, C. T., Kathiresan, S., & Hegele, R. A. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r009720 · Cited by 263
Hypolipidemic effects of proanthocyanidins and their underlying biochemical and molecular mechanisms
Bladé, C., Arola, L., & Salvadó, M. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900476 · Cited by 253
Lipoprotein lipase and its regulators: an unfolding story
Wu, S. A., Kersten, S., & Qi, L. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.11.005 · Cited by 225
Desai, U., Lee, E.-C., Chung, K., Gao, C., Gay, J., Key, B., Hansen, G., Machajewski, D., Platt, K. A., Sands, A. T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705041104 · Cited by 175
Lai, C.-Q., Demissie, S., Cupples, L. A., Zhu, Y., Adiconis, X., Parnell, L. D., Corella, D., & Ordovas, J. M. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400192-jlr200 · Cited by 163
Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation
Rip, J., Nierman, M. C., Ross, C. J., Jukema, J. W., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., & Kuivenhoven, J. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000219283.10832.43 · Cited by 157
Sundaram, M., & Yao, Z. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-35 · Cited by 154
Novel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149
Nilsson, S. K., Christensen, S., Raarup, M. K., Ryan, R. O., Nielsen, M. S., & Olivecrona, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802721200 · Cited by 111
Lalanne, F., Lambert, G., Amar, M. J. A., Chétiveaux, M., Zaïr, Y., Jarnoux, A.-L., Ouguerram, K., Friburg, J., Seidah, N. G., Brewer, H. B., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400396-jlr200 · Cited by 104
“to be decreased in mice upon adenoviral overexpression of the hypotriglyceridemic gene apoA-5 by the tyloxapol method (29), whereas, also using tyloxapol, others have”
MethodApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition
Chen, Y. Q., Pottanat, T. G., Zhen, E. Y., Siegel, R. W., Ehsani, M., Qian, Y.-W., & Konrad, R. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100068 · Cited by 82
Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000203519.25116.54 · Cited by 70
Qi, L., Liu, S., Rifai, N., Hunter, D., & Hu, F. B. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.006 · Cited by 67
Hepatic ABCA1 and VLDL triglyceride production
Liu, M., Chung, S., Shelness, G. S., & Parks, J. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.020 · Cited by 43
“Hepatic apoAV expression reduces TG secretion and VLDL particle size in oleate-stimulated McA cells [73] and in mice with liver apoAV overexpression [74].”
Huang, X., Zhao, S., Bai, L., Hu, M., Zhao, W., & Zhang, Q. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00350.x · Cited by 36
“…pathways of apoAV have been proposed: (i) inhibitory effects on production and secretion of very low density lipoprotein (VLDL) (Schaap et al., 2004); (ii) stimulation of lipoprotein lipase (LPL)-mediated triglyceride hydrolysis (Grosskopf et al., 2005); and (iii) acceleration…”
BackgroundInfluentialInfluence of apolipoprotein A-V on hepatocyte lipid droplet formation
Gao, X., Forte, T. M., & Ryan, R. O. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.065 · Cited by 16
Ibi, D., Boot, M., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R., Rensen, P. C. N., Karpe, F., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100193 · Cited by 9
Self-citation
Metadata
- Authors
- Schaap, F. G., Rensen, P. C. N., Voshol, P. J., Vrins, C., van der Vliet, H. N., Chamuleau, R. A. F. M., Havekes, L. M., Groen, A. K., & van Dijk, K. W.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-07
- Volume
- 279
- Issue
- 27
- Pages
- 27941-27947
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2078074803
- Cited by
- 300
- References
- 28
- FWCI
- 17.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.